Xiaolin Zhang, PhD, discusses findings from the phase 2 study exploring a novel oral agent for the treatment of EGFR-mutated non–small cell lung cancer.
Xiaolin Zhang, PhD
Advertisement
Xiaolin Zhang, PhD, is the chief executive officer of Dizal Pharmaceuticals.
Articles by Xiaolin Zhang, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
2
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
3
Vilamakitug Meets Phase 2 Efficacy Criterion in Refractory Metastatic Colorectal Cancer
4
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
5